

Time	Sessions
08:30–09:00	<p>20 Years of Innovation: An Evolution of Progress</p> <p>Through pioneering commitment and innovation, MMV and partners have achieved enormous success in reinvigorating the malaria therapeutic pipeline. 20 years ago, malaria had re-emerged as a major killer, drug resistance was rife and new drugs were desperately needed. Today, MMV and partners have helped to build the richest drug pipeline in history and have brought forward 12 new products that are saving lives.</p> <p>In this session you will:</p> <ul style="list-style-type: none"> • Hear from Mr Mauro Poggia, the Conseiller d'État, Canton of Geneva, who will introduce Geneva as an international hub for partnerships dedicated to global health; and Dr David Reddy, Chief Executive Officer, MMV, who will present the key lessons learned during MMV's first 20 years, its vision for how it will contribute to the fight against malaria going forward, supporting partners in malaria endemic countries and pursuing the long-term goal of malaria eradication • Watch an inspiring animation celebrating the last 20 years of progress, marking key milestones and achievements through the years
09:00–10:15	<p>Stronger Together: Lessons Learned and Barriers Broken</p> <p>We invite you to enjoy this live demonstration by MMV and partners of how the power of the network has enabled challenges to be overcome and innovative solutions to be introduced. Continued collaboration will be key as we remain committed to malaria elimination and defeating the disease for good.</p> <p>In this session you will:</p> <ul style="list-style-type: none"> • Witness the rich history behind MMV's achievements unfold as we invite staff and partners to share their stories and insights • Reflect Reflect on lessons learned and adaptations made with Dr Tim Wells, MMV's Chief Scientific Officer and Andrea Lucard, MMV's Executive Vice President, Corporate Affairs, who will review how innovative solutions have helped overcome key obstacles to progress
10:15–11:00	<p>Coffee/tea break</p>
11:00–12:00	<p>Working Towards a Common Goal: Malaria and the 2030 Agenda for Sustainable Development</p> <p>A world without malaria would contribute to the objectives of the UN Sustainable Development Goals (SDGs) and Universal Health Coverage (UHC), significantly improving health and economies. MMV works with partners to ensure its malaria interventions support the WHO Global Technical Strategy (GTS) and the wider objectives of these global goals. With concerted and combined effort, we will have met the World Health Organization (WHO) and UN goals to reduce malaria case incidence and mortality rates by at least 90% by 2030, and will be on the road to global eradication. Donor countries have a key role to play in this effort, and their individual priorities of the 2030 Agenda goals will have a vital impact on the global fight against malaria.</p> <p>In this session you will:</p> <ul style="list-style-type: none"> • Understand the importance of malaria in the context of wider global health needs, as envisioned by the WHO and hear Dr Pedro Alonso, Global Malaria Programme Director, WHO, review the GTS for malaria, including the progress made towards achieving these goals and challenges that must be overcome • Watch an interactive panel of distinguished government representatives from donor countries discuss the importance of malaria elimination within the context of their countries' SDG priorities
12:00–13:00	<p>Knowledge Shared is Knowledge Squared: Big Data and Capacity Development as Drivers of Future Innovation</p> <p>Although considerable progress has been made, future innovation is required to achieve our goals and prevent malaria returning. Through the commitment to sharing data, and developing new, effective and affordable medicines, we can accelerate malaria control and increase the operational feasibility of its eradication.</p> <p>In this session you will:</p> <ul style="list-style-type: none"> • Learn about the role of malaria-endemic countries in driving joint purpose, endeavour and innovation from Ms Joy Phumaphi, Executive Secretary, ALMA • Understand the use of Big Data to design compounds and develop new targets in a session chaired by Dr Dan Hartman, Director Integrated Development, Bill and Melinda Gates Foundation • Watch a series of short talks by esteemed researchers on the importance of technology and knowledge-sharing when considering the future of global health, on the drivers of innovation in African science and medicine, and the future of drug Research and Development in the private sector • Listen to MMV's, Vice President, Head of Product Development, Dr Wiweka Kaszubaska, present the case for innovation in future product development to meet the needs of all populations at risk of malaria

Time	Sessions
13:00–14:30	Lunch
14:30–15:30	<p>The Long Last Mile: Challenges of Access to Medicines and Comprehensive Case Management</p> <p>The drugs developed and made accessible through MMV's efforts are among the most cost-effective health interventions for low- and middle-income countries. Continuous application of innovative approaches to increase access to malaria treatments is of utmost importance as, unfortunately, access to many of these medicines remains a challenge.</p> <p>In this session you will:</p> <ul style="list-style-type: none"> • Get an update on the US global malaria control programme from Dr Kenneth Staley, Coordinator of the US Government Activities to Combat Malaria, US Agency for International Development (USAID) • Hear a panel of experienced in-country experts discuss examples of challenges in accessing malaria treatments and pioneering solutions for how they were overcome through: <ul style="list-style-type: none"> ○ enhanced collection and sharing of epidemiological and operational data ○ innovative strategies such as the encouragement of a community-driven approach to mobilize access to malaria treatment in hard-to-reach rural areas ○ projects encouraging the local production of malaria commodities in Africa to improve cost-effectiveness ○ the development of new diagnostic tools to maximize access of antimalarials to eligible patients ○ extending the age range for administering seasonal malaria chemoprevention to children above 5 years of age – pushing boundaries to increase impact • Listen to Mr George Jagoe, Executive Vice President of Access and Product Management, discuss MMV's commitment to providing end-to-end support for countries with the greatest need
15:30–16:30	<p>The Fight Must Continue: Mobilising the Next Generation of Research</p> <p>Future outlook – almost 2 million lives and counting, have been saved by MMV-co-developed medicines. However, the fight must continue. A new generation of innovative technologies is needed that can address drug resistance, block onward transmission and prevent disease in non-immune populations. These tools are vital for healthcare providers and researchers to continue moving forward.</p> <p>In this session you will:</p> <ul style="list-style-type: none"> • Feel empowered by this rapid-fire session comprising a series of Turbo Talks • Hear about pioneering projects from 10 inspirational researchers and malaria advocates dedicated to one clear mission: global malaria eradication for good • Be inspired by Dr Fredros Okumu, Director of Science, Ifakara Health Institute, who will be sharing his passionate opinions on the future of antimalarial drug development
16:30–17:00	<p>Meeting close</p> <p>Building on 20 years of unprecedented progress achieved by overcoming many challenges, MMV is well positioned to deliver its vision of a world in which innovative medicines cure and protect the vulnerable and under-served populations at risk of malaria.</p> <p>In this session you will:</p> <ul style="list-style-type: none"> • Join us in consolidating our commitment to malaria eradication through the provision of co-developed high-quality antimalarial therapies that can be used by all.

* Questions for the panel can be submitted online prior to the event.